Preliminary evidence suggests that the combination of magnesium and ibogaine, an atypical psychedelic, may be a promising treatment for post-traumatic stress disorder (PTSD), opioid use disorder, and traumatic brain injury (TBI). The "mystical" experience elicited by ibogaine, which is characterized by feelings of awe, selflessness, and transcendence, is correlated with improvements in PTSD...
Abstract Ibogaine has shown early therapeutic promise for substance use disorders (SUD) and post-traumatic stress disorder in veterans, but concerns about treatment-associated cardiac arrhythmia and death have constrained clinical development. Whether this risk is uniform across indications or concentrated in specific populations is unknown. We conducted a retrospective multisite study of...
Abstract Post-traumatic stress disorder (PTSD) is a debilitating condition that affects millions of veterans. A recent observational study in 30 veterans showed that a single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD up to twelve months later. Although a prior study demonstrated that ibogaine transiently alters electroencephalography (EEG) power in...